To access this element change to forms mode OFF
Grant Award View - GA276587
The Neurokinin 3 Receptor is a New Target for the Treatment of Autism...
GA ID:
GA276587
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
27-Oct-2022
Publish Date:
19-Dec-2022
Category:
Medical Research
Grant Term:
1-Jan-2023 to 31-Dec-2026
Value (AUD):
$996,128.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 21/22 1.1 Health and Medical Research
Grant Program:
Ideas Grants
Grant Activity:
The Neurokinin 3 Receptor is a New Target for the Treatment of Autism Spectrum Disorder.
Purpose:
No treatment has been shown to be effective in treating the core symptoms of autism spectrum disorder. We have discovered a molecule, named NK3R, which plays a key role in the development of autism. Studying how this molecule works in mouse models of autism will help us to better understand the disorder and enable us to identify the signs of abnormal brain function. The outcomes of this 4-year research will ultimately enable us to propose new strategies to treat the symptoms of autism.
GO ID:
GO Title:
Ideas Grants 2022
Internal Reference ID:
2022/GNT2019416
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
Australian National University
Recipient ABN:
52 234 063 906
Grant Recipient Location
Suburb:
Canberra City
Town/City:
Canberra City
Postcode:
2600
State/Territory:
ACT
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
ACT, Overseas
Postcode:
Multiple
Country:
AUSTRALIA, FRANCE